SCHEMBL283419

SCHEMBL283419

COC(=O)C(N)c1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.64
TSHR P16473 3/20 0.49
CYP1A2 P05177 2/20 0.49
CYP2D6 P10635 2/20 0.49
CYP3A4 P08684 1/20 0.49
MAPK1 P28482 1/20 0.49
HSD17B10 Q99714 1/20 0.49
MEN1 O00255 2/20 0.47
ALDH1A1 P00352 2/20 0.47
PTGS1 P23219 1/20 0.47
PTGS2 P35354 1/20 0.47
LMNA P02545 1/20 0.47
PKM P14618 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
CTSD P07339 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL318862 1.00 KMT2A (0.64) KMT2ATSHRCYP1A2CYP2D6CYP3A4
SCHEMBL318460 1.00 KMT2A (0.64) KMT2ATSHRCYP1A2CYP2D6CYP3A4
SCHEMBL29841724 1.00 KMT2A (0.64) KMT2ATSHRCYP1A2CYP2D6CYP3A4
Hydrochloric Acid SCHEMBL852494 0.98 KMT2A (0.62) KMT2ATSHRCYP1A2CYP2D6CYP3A4
Hydrochloric Acid SCHEMBL1143309 0.98 KMT2A (0.62) KMT2ATSHRCYP1A2CYP2D6CYP3A4
Hydrochloric Acid SCHEMBL852495 0.98 KMT2A (0.62) KMT2ATSHRCYP1A2CYP2D6CYP3A4
SCHEMBL7252180 0.89 KMT2A (0.48) KMT2ATSHRCYP1A2CYP2D6CYP3A4
SCHEMBL5514179 0.89 KMT2A (0.52) KMT2ACYP1A2CYP3A4ALDH1A1PTGS2
Cadaverine Tartrate SCHEMBL32662849 0.88 KMT2A (0.51) KMT2ATSHRCYP1A2CYP2D6CYP3A4
SCHEMBL27865114 0.86 KMT2A (0.53) KMT2ATSHRCYP1A2CYP2D6CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 456 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101698647-B Synthesis method of 2,5-diamino benzene ethanol YIXING XINYU CHEMICAL CO LTD 2012-10-03 CN claimed
CN-101698647-A Synthesis method of 2,5-diamino benzene ethanol YIXING XINYU CHEMICAL CO LTD 2010-04-28 CN claimed
US-20070161633-A1 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (1-aminocarbonyl)eth-1-yl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases ELAN PHARMACEUTICALS, INC. (US) 2007-07-12 US claimed
WO-2002020819-A2 AN ENZYMATIC PROCESS FOR PREPARING β-LACTAM COMPOUNDS DSM N.V. (NL) 2002-03-14 WO claimed
EP-1186668-A1 An enzymatic process for preparing Beta-lactam compounds DSM N.V. (NL) 2002-03-13 EP claimed
WO-1998022494-A9 METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS 1998-08-20 WO claimed
US-12286435-B2 Compound having benzo seven-membered ring structure, preparation method therefor, and use thereof BIONNA (BEIJING) MEDICAL TECHNOLOGY CO., LTD. (CN) 2025-04-29 US disclosed
CN-118440082-B Organic compound, preparation method and application thereof 天合光能股份有限公司 2024-10-22 CN disclosed
CN-118480009-A Compositions and methods for modulating short-chain dehydrogenase activity 卡斯西部储备大学 2024-08-13 CN disclosed
CN-118440082-A Organic compound, preparation method and application thereof 天合光能股份有限公司 2024-08-06 CN disclosed
CN-118390075-A Synthesis method of glycine ester compound 中国计量大学 2024-07-26 CN disclosed
EP-3892272-B1 BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE DANA FARBER CANCER INST INC (US) 2024-07-24 EP disclosed
EP-3919479-B1 COMPOUND HAVING BENZO SEVEN-MEMBERED RING STRUCTURE, PREPARATION METHOD THEREFOR, AND USE THEREOF BIONNA BEIJING MEDICAL TECH CO LTD (CN) 2024-03-20 EP disclosed
EP-0404737-A2 New R(-) 3-quinuclidinol derivatives BOEHRINGER INGELHEIM ITALIA S.p.A. (IT) 1990-12-27 EP disclosed
EP-0163094-B1 PREPARATION OF OPTICALLY-ACTIVE ALPHA-SUBSTITUTED PHENYLACETIC ACIDS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1989-08-02 EP disclosed
US-4661588-A ANTIBIOTICS TOYO JOZO KABUSHIKI KAISHA (JP) 1987-04-28 US disclosed
EP-0163094-A2 Preparation of optically-active alpha-substituted phenylacetic acids E.I. DU PONT DE NEMOURS AND COMPANY (US) 1985-12-04 EP disclosed
US-4505854-A Optically active dipeptides and the use thereof as tissue dissolving and histolytic agent in human beings NATTERMANN & CIE GMBH (DE) 1985-03-19 US disclosed
US-4075405-A CYANOGEN HALIDE TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) 1978-02-21 US disclosed
US-4001279-A CARRY INSOLUBLE REAGENT SUBSTANCES INTO SOLUTION IN NON-HYDROXYLIC MEDIA; CROWN COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1977-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161633-A1 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (1-aminocarbonyl)eth-1-yl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases BDKRB1, BDKRB2, HRH2 KMT2A 2943/4885TSHR 1217/4885CYP1A2 689/4885
US-12286435-B2 Compound having benzo seven-membered ring structure, preparation method therefor, and use thereof BRD4, BRD7, BICRA KMT2A 888/4885TSHR 3099/4885CYP1A2 3192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.